LEXICON PHARMACEUTICALS, INC.
LXRXLexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
Drugs in Pipeline
15
Phase 3 Programs
6
Upcoming Catalysts
2
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
Sotagliflozin (SAR439954)
Type 2 Diabetes Mellitus
Sulfonylurea
Type 2 Diabetes Mellitus
Glimepiride
Type 2 Diabetes Mellitus
Telotristat etiprate
Carcinoid Syndrome
Insulin glargine (HOE901)
Type 2 Diabetes Mellitus
Sotagliflozin
Type 2 Diabetes Mellitus
LX7101 (0.125%)
Primary Open-angle Glaucoma
LX1031 High Dose
Irritable Bowel Syndrome
LX9211
Diabetic Peripheral Neuropathy
LX9211 (blinded)
Diabetic Peripheral Neuropathic Pain
LX4211 Low Dose
Type 2 Diabetes Mellitus
LX3305 low dose
Rheumatoid Arthritis
75 mg LX4211
Type 2 Diabetes Mellitus
250 mg LX1033 tablets
Irritable Bowel Syndrome
LX6171 High Dose
Age-Related Memory Disorders
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Sotagliflozin (SAR439954) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Sulfonylurea | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Glimepiride | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Telotristat etiprate | Phase 3 | Carcinoid Syndrome | - | - |
Insulin glargine (HOE901) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Sotagliflozin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
LX7101 (0.125%) | Phase 2 | Primary Open-angle Glaucoma | - | - |
LX1031 High Dose | Phase 2 | Irritable Bowel Syndrome | - | - |
LX9211 | Phase 2 | Diabetic Peripheral Neuropathy | - | - |
LX9211 (blinded) | Phase 2 | Diabetic Peripheral Neuropathic Pain | - | - |
LX4211 Low Dose | Phase 2 | Type 2 Diabetes Mellitus | - | - |
LX3305 low dose | Phase 2 | Rheumatoid Arthritis | - | - |
75 mg LX4211 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
250 mg LX1033 tablets | Phase 2 | Irritable Bowel Syndrome | - | - |
LX6171 High Dose | Phase 2 | Age-Related Memory Disorders | - | - |